XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012

Effective Date 1/11/2012

JAZZ Fair Value Estimate
Premium
JAZZ Consider Buying
Premium
JAZZ Consider Selling
Premium
JAZZ Fair Value Uncertainty
Premium
JAZZ Economic Moat
Premium
JAZZ Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
COLELLA SAMUEL D
  2. Issuer Name and Ticker or Trading Symbol
JAZZ PHARMACEUTICALS INC [JAZZ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O VERSANT VENTURES, 3000 SAND HILL ROAD, BLDG 4 STE 210
3. Date of Earliest Transaction (Month/Day/Year)
01/11/2012
(Street)

MENLO PARK, CA 94025
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/11/2012   M   10,000 A $12.75 10,000 D  
Common Stock 01/11/2012   F(1)   2,623 D $48.6 7,377 D  
Common Stock 01/11/2012   M   10,000 A $7.84 17,377 D  
Common Stock 01/11/2012   F(1)   1,613 D $48.6 15,764 D  
Common Stock 01/11/2012   M   10,000 A $6.33 25,764 D  
Common Stock 01/11/2012   F(1)   1,302 D $48.6 24,462 D  
Common Stock 01/11/2012   M   12,500 A $8.23 36,962 D  
Common Stock 01/11/2012   F(1)   2,116 D $48.6 34,846 D  
Common Stock 01/11/2012   M   12,500 A $34.99 47,346 D  
Common Stock 01/11/2012   F(1)   8,999 D $48.6 38,347 D  
Common Stock               1,488,676 I By Versant Venture Capital II, L.P.(2)
Common Stock               28,260 I By Versant Affiliates Fund II-A, L.P.(3)
Common Stock               13,247 I By Versant Side Fund II, L.P.(4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) $12.75 01/11/2012   M     10,000   (5) 08/15/2017 Common Stock 10,000 $ 0 0 D  
Option (right to buy) $7.84 01/11/2012   M     10,000   (6) 08/15/2018 Common Stock 10,000 $ 0 0 D  
Option (right to buy) $6.33 01/11/2012   M     10,000   (7) 08/16/2019 Common Stock 10,000 $ 0 0 D  
Option (right to buy) $8.23 01/11/2012   M     12,500   (8) 08/25/2020 Common Stock 12,500 $ 0 0 D  
Option (right to buy) $34.99 01/11/2012   M     12,500   (9)(10) 11/04/2021 Common Stock 12,500 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
COLELLA SAMUEL D
C/O VERSANT VENTURES
3000 SAND HILL ROAD, BLDG 4 STE 210
MENLO PARK, CA 94025
  X      

Signatures

 /s/ Carol A. Gamble as attorney-in-fact for Samuel D. Colella   01/13/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents shares withheld by the Issuer for cashless exercise of nonstatutory stock options solely to cover exercise price.
(2) The shares are owned by Versant Venture Capital II, L.P. Versant Ventures II, LLC is the general partner of Versant Venture Capital II, L.P. The Reporting Person is a managing member of Versant Ventures II, LLC and shares voting and investment power over the shares held by Versant Venture Capital II, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Versant Venture Capital II, L.P. except to the extent of his proportionate pecuniary interest therein.
(3) The shares are owned by Versant Affiliates Fund II-A, L.P. Versant Ventures II, LLC is the general partner of Versant Affiliates Fund II-A, L.P. The Reporting Person is a managing member of Versant Ventures II, LLC and shares voting and investment power over the shares held by Versant Affiliates Fund II-A, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Versant Affiliates Fund II-A, L.P. except to the extent of his proportionate pecuniary interest therein.
(4) The shares are owned by Versant Side Fund II, L.P. Versant Ventures II, LLC is the general partner of Versant Side Fund II, L.P. The Reporting Person is a managing member of Versant Ventures II, LLC and shares voting and investment power over the shares held by Versant Side Fund II, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Versant Side Fund II, L.P. except to the extent of his proportionate pecuniary interest therein.
(5) This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2007.
(6) This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2008.
(7) This nonstatutory stock option vested in 12 equal monthly installments from August 17, 2009.
(8) This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2010.
(9) This nonstatutory stock option has a vesting schedule of 100% vesting in 12 equal monthly installments from August 15, 2011.
(10) On October 24, 2011, the Board of Directors of the Issuer approved the full vesting of unvested nonstatutory stock options held by the Issuer's officers and non-employee directors, including the Reporting Person. Such vesting acceleration became effective on December 13, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filling

Jazz Pharmaceuticals PLC XNAS:JAZZ Stock - Get Insider Activity SEC Filing of Jazz Pharmaceuticals PLC XNAS:JAZZ stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012  |  Next: XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012